Erschienen in:
01.10.2019 | ASO Author Reflections
ASO Author Reflections: Venous Thromboembolism after CRS/HIPEC
verfasst von:
Joel M. Baumgartner, MD, MAS, Sohini Khan, MD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2019
Einloggen, um Zugang zu erhalten
Excerpt
Stasis, hypercoagulability, and endothelial injury are the classic risk factors associated with venous thromboembolism (VTE) and are arguably all present after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Indeed, malignancy and extensive cancer surgery are known to increase the VTE risk compared with noncancer surgery.
1 However, the incidence of VTE after CRS/HIPEC has not been well defined, nor have unique risk factors for VTE in this population been identified. Furthermore, although pharmacothromboprophylaxis guidelines have been shown to be effective in preventing VTE after major cancer surgery,
2 pharmacoprophylaxis strategies for VTE have not been investigated after CRS/HIPEC. Therefore, we wanted to better define the incidence, risk factors, and prevention strategies of VTE in these patients at our institution. …
